Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021
Authors:
Open Access
- 1 January 2023
- journal article
- research article
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 5 (17) , 379-384
Abstract
What is already known on this topic? Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation. What is added by this report? This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal. What are the implications for public health practice? Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.Keywords
This publication has 7 references indexed in Scilit:
- Factors Associated with PCV13 Vaccine Hesitancy in Parents under an Innovative Immunization Strategy: a Cross-Sectional Study-Weifang City, Shandong Province, China, 20212023
- National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: Modelled estimates for 2010–17The Lancet Regional Health - Western Pacific, 2022
- Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: A database analysis based on birth cohorts from 2012 to 2020Vaccine, 2021
- Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018Vaccine, 2019
- Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysisThe Lancet Global Health, 2019
- Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in ChinaPLOS ONE, 2018
- Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014Clinical Infectious Diseases, 2016